REVIEW
|
doi:10.20944/preprints202410.0929.v1
Subject:
Medicine And Pharmacology,
Internal Medicine
Keywords:
SGLT2 inhibitors; sodium-glucose cotransporter-2 inhibitors; empagliflozin; canagliflozin; dapagliflozin; GLP-1 receptor agonists; glucagon-like peptide-1 receptor agonists; liraglutide; semaglutide; dulaglutide; cardiovascular outcomes; heart failure; myocardial infarction; stroke; MACE; mortality; type 2 diabetes; T2D
Online: 11 October 2024 (16:59:11 CEST)